Investigational Drug Information for Giredestrant
✉ Email this page to a colleague
What is the drug development status for Giredestrant?
Giredestrant is an investigational drug.
There have been 16 clinical trials for Giredestrant.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2022.
The most common disease conditions in clinical trials are Breast Neoplasms, Endometrial Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and MedSIR.
There is one US patent protecting this investigational drug and thirty-one international patents.
Summary for Giredestrant
| US Patents | 1 |
| International Patents | 31 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2022-06-01) |
| Vendors | 26 |
Recent Clinical Trials for Giredestrant
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Hoffmann-La Roche | Phase 3 |
| A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | MedSIR | Phase 2 |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer | Hoffmann-La Roche | Phase 2 |
Clinical Trial Summary for Giredestrant
Top disease conditions for Giredestrant
Top clinical trial sponsors for Giredestrant
US Patents for Giredestrant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Giredestrant | ⤷ Subscribe | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Giredestrant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Giredestrant | Argentina | AR103081 | 2034-12-18 | ⤷ Subscribe |
| Giredestrant | Australia | AU2015367509 | 2034-12-18 | ⤷ Subscribe |
| Giredestrant | Australia | AU2020200407 | 2034-12-18 | ⤷ Subscribe |
| Giredestrant | Brazil | BR112017007662 | 2034-12-18 | ⤷ Subscribe |
| Giredestrant | Canada | CA2963736 | 2034-12-18 | ⤷ Subscribe |
| Giredestrant | Chile | CL2017000814 | 2034-12-18 | ⤷ Subscribe |
| Giredestrant | Chile | CL2019000431 | 2034-12-18 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
